NASHUA, N.H., June 12 /PRNewswire-FirstCall/ -- iCAD(R), Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions, today announced signing of a development and distribution agreement with Agfa, a leading provider of IT enabled clinical workflow and diagnostic image solutions. With this agreement, iCAD's SecondLook Digital CAD solution is now available for Agfa's direct digital mammography systems. Agfa will market and sell this solution to customers globally, initially focusing on Europe and Asia. In the future, iCAD will develop a SecondLook Digital solution customized for Agfa's other market-leading mammography systems.
"We are encouraged by the broad scope of this agreement and look forward to working with Agfa to leverage our powerful systems together throughout the world," said Ken Ferry, President and CEO of iCAD. "We anticipate the collective iCAD and Agfa solution having an immediate impact in the market, particularly in Europe. Additionally, we believe iCAD and Agfa's collective future mammography solutions will significantly improve cancer detection and enhance digital workflow with CAD."
Using sophisticated algorithms, iCAD detection software enables earlier cancer detection which can allow less invasive and more effective treatment options, enhancing patient care. iCAD's algorithms have been shown to detect up to 72 percent of actionable missed cancers an average of 15 months earlier than mammography alone.
About Agfa Healthcare
Agfa offers a selection of proven solutions across the healthcare spectrum that includes conventional and digital imaging options as well as a complete range of information systems. Agfa customers around the world benefit from the combination of clinically specific features with hospital-wide connectivity, enabling a seamless flow of information and a 360-degree view of patients and healthcare facilities.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer- Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by almost one thousand women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit www.icadmed.com.
For iCAD investor relations, contact Kevin McGrath of Cameron Associates at
212-245-4577 or via email at email@example.com
For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at
781-684-0770 or via email at firstname.lastname@example.org
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.